

Org nr 556966-4955
June 8, 2026



Elicera's Nomination Committee Proposes Margareth Jorvid as New Chair of the Board

Gothenburg, June 8, 2026 – The Nomination Committee of Elicera Therapeutics AB (publ) proposes Margareth Jorvid as the new Chair of the Board. Agneta Edberg, who has served as Chair since 2021, has announced that she wishes to step down from the Chair position but is standing for re-election as an ordinary board member.

Agneta Edberg comments:

“After seven years on the Board, six of which as Chair, I believe it is time for a change in the leadership of the Board. I am very proud of what Elicera has achieved during these years and look forward to continuing to contribute as an ordinary board member. Margareth will be an excellent Chair.”

Margareth Jorvid comments:

“I am honored and very pleased to be proposed as Chair of the Board. Elicera is in an exciting phase with promising clinical results and a unique platform in cell and gene therapy. I look forward to leading the Board in its work to develop the company and maximize the value of its strong scientific foundation for the benefit of patients and shareholders.”

Other proposals from the Nomination Committee:

- Margareth Jorvid proposed as new Chair of the Board
- Agneta Edberg proposed as ordinary board member
- Di Yu proposed as new ordinary board member (previously deputy)
- Magnus Essand proposed as new deputy board member (previously ordinary member)
- Re-election of Christina Herder and Sharon Longhurst as ordinary board members

The Nomination Committee further proposes the re-election of Cedra Väst KB as auditor, with Kristoffer Håkansson as the auditor in charge.

Proposed fees:

- Chair: SEK 360,000
- Other non-executive board members: SEK 150,000 each

The Nomination Committee has consisted of Magnus Essand (Chair), Di Yu and Jamal El-Mosleh, who together represented approximately 20 percent of the votes prior to the latest share issue.

The Annual General Meeting will be held on 25 June 2026 at 13:00 at Advokatfirman Delphi's offices in Stockholm, Mäster Samuelsgatan 17.

This press release has been approved by the Board of Directors and the CEO for publication. The information was submitted, through the care of the contact person below, for public release on 8 June 2026 at 08:40 CET.

For further information, please contact:

Jamal El-Mosleh, CEO, Elicera Therapeutics AB (publ)

Phone: +46 (0) 703 31 90 51

jamal.elmosleh@elicera.com

Certified Advisor

DNB Carnegie Investment Bank (publ)

About Elicera Therapeutics AB

Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company's CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company's share is traded on Nasdaq First North Growth Market. For additional information, visit www.elicera.com.